摘要
目的探讨经皮冠状动脉介入治疗(PCI)术中应用重组人尿激酶原对急性心肌梗死(AMI)患者血管再通及短期心功能的影响。方法选取2020年1月至2021年5月于本院就诊的100例AMI患者作为研究对象,按照随机数字表法分为两组,各50例。对照组应用常规治疗联合PCI术,观察组在对照组基础上应用重组人尿激酶原治疗,比较两组手术前后心功能指标[左心室收缩末期内径(LVEDS)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]、校正的心肌梗死溶栓治疗(TIMI)血流帧数计数(CTFC)、血管再通情况、不良心血管事件(MACE)发生情况、不良反应发生情况。结果术前,两组LVEDS、LVEDD、LVEF、CTFC比较差异无统计学意义;术后,两组LVEDS、LVEDD均短于术前,CTFC均低于术前,LVEF均高于术前,且观察组LVEDS、LVEDD均短于对照组,CTFC均低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。观察组血管再通率为96.00%,高于对照组的80.00%,差异有统计学意义(P<0.05);观察组MACE发生率为6.00%,低于对照组的20.00%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论在PCI术中应用重组人尿激酶原可有效改善AMI患者心功能,快速疏通血管,降低MACE及不良反应发生风险。
Objective To investigate the effect of recombinant human urokinase during percutaneous coronary intervention(PCI)on vascular recanalization and short-term cardiac function in patients with acute myocardial infarction(AMI).Methods A total of 100 AMI patients from January 2020 to May 2021 were selected as the research subjects,and they were divided into two groups according to the random number table method,with 50 cases in each group.The control group was treated with conventional treatment combined with PCI,and the observation group was treated with recombinant human urokinase on the basis of the control group,and the cardiac function indexes(left ventricular endsystolic dimension[LVEDS],left ventricular end-diastolic dimension[LVEDD],left ventricular ejection fraction[LVEF]),corrected myocardial infarction thrombolytic therapy(TIMI)corrected timi frame count(CTFC),vascular recanalization,occurrence of adverse cardiovascular events(MACE),and occurrence of adverse reactions were compared between the two groups.Results There was no significant difference between LVEDS,LVEDD,LVEF and CTFC between the two groups before surgery;after surgery,LVEDS and LVEDD were shorter than preoperative,CTFC was lower than preoperative,LVEF was higher than preoperative,and LVEDS and LVEDD in the observation group were shorter than those in the control group,CTFC were lower than in the control group,and LVEF was higher than that in the control group,and the difference was statistically significant(P<0.05).The vascular recanalization rate in the observation group was 96.00%,which was higher than that of the control group by 80.00%,and the difference was statistically significant(P<0.05),and the incidence of MACE in the observation group was 6.00%,which was lower than 20.00%of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The application of recombinant human urokinase in PCI can effectively improve car
作者
石凡
吴春华
裴小英
SHI Fan;WU Chunhua;PEI Xiaoying(Department of Cardiovascular Medicine,Jiujiang First People's Hospital,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2022年第28期149-152,共4页
Contemporary Medicine
基金
江西省卫生计生委科技计划(202140254)。
关键词
急性心肌梗死
经皮冠状动脉介入治疗
重组人尿激酶原
心功能
Acute myocardial infarction
Percutaneous coronary intervention
Recombinant human urokinase
Cardiac function
